Literature DB >> 15648254

Effect of pluronic P85 on ATPase activity of drug efflux transporters.

Elena V Batrakova1, Shu Li, Yili Li, Valery Yu Alakhov, Alexander V Kabanov.   

Abstract

PURPOSE: Pluronic block copolymers are potent sensitizers of multi-drug resistant (MDR) cancer cells. The sensitization effect by Pluronics is a result of two processes acting in concert: i) intracellular ATP depletion, and ii) inhibition of ATPase activity of drug efflux proteins. This work characterizes effects of Pluronic P85 on ATPase activities of Pgp, MRP1, and MRP2 drug efflux transport proteins and interaction of these proteins with their substrates, vinblastine, and leucotriene C4.
METHODS: Using membranes overexpressing Pgp, MRP1, and MRP2, the current study evaluates effects of Pluronic P85 (P85) on the kinetic parameters (Vmax, Km, Vmax/Km) of ATP hydrolysis by these ATPases.
RESULTS: The decreases in the maximal reaction rates (Vmax) and increases in apparent Michaelis constants (Km) for these transporters in the presence of various concentrations of P85 were observed. The mechanism of these effects may involve i) conformational changes of the transporter due to membrane fluidization and/or ii) nonspecific steric hindrance of the drug-binding sites by P85 chains embedded into cellular membranes. The extent of these alterations was increased in the row MRP1 < MRP2 << Pgp.
CONCLUSIONS: These data suggest that there are unifying pathways for the inhibition of Pgp and MRPs by the block copolymer. However, the effect of P85 on Pgp ATPase activity is considerably greater compared with the effects on MRP1 and MRP2 ATPases. This may be a reason for greater inhibitory effects of Pluronic in Pgp- compared with MRP-overexpressing cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15648254      PMCID: PMC2677181          DOI: 10.1007/s11095-004-7675-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  42 in total

Review 1.  ABC transporters: from microorganisms to man.

Authors:  C F Higgins
Journal:  Annu Rev Cell Biol       Date:  1992

2.  Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase.

Authors:  B Sarkadi; E M Price; R C Boucher; U A Germann; G A Scarborough
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

Review 3.  Reversal of multidrug resistance to cancer chemotherapy.

Authors:  B Leyland-Jones; W Dalton; G A Fisher; B I Sikic
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

4.  Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3',4'-pentamethoxyflavone (Sinensetin).

Authors:  Cheol Hee Choi; Kyung Hoon Sun; Chun San An; Jin Cheol Yoo; Kyung Soo Hahm; In Hwa Lee; Jae Kyung Sohng; Youn Chul Kim
Journal:  Biochem Biophys Res Commun       Date:  2002-07-26       Impact factor: 3.575

5.  Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells.

Authors:  Elena V Batrakova; Shu Li; Valery Yu Alakhov; Donald W Miller; Alexander V Kabanov
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

6.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

Authors:  F Hyafil; C Vergely; P Du Vignaud; T Grand-Perret
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

7.  The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins.

Authors:  Katrijn Bogman; Françoise Erne-Brand; Jochem Alsenz; Jürgen Drewe
Journal:  J Pharm Sci       Date:  2003-06       Impact factor: 3.534

8.  Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85.

Authors:  Elena V Batrakova; Shu Li; Valery Yu Alakhov; William F Elmquist; Donald W Miller; Alexander V Kabanov
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

9.  Real-time monitoring of P-glycoprotein activation in living cells.

Authors:  Ewa Landwojtowicz; Pierluigi Nervi; Anna Seelig
Journal:  Biochemistry       Date:  2002-06-25       Impact factor: 3.162

10.  Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer.

Authors:  S Danson; D Ferry; V Alakhov; J Margison; D Kerr; D Jowle; M Brampton; G Halbert; M Ranson
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

View more
  39 in total

1.  Combined pluronic P85- and ultrasound contrast agents-mediated gene transfection to HepG2 cells.

Authors:  Xijun Zhang; Kaiyan Li; Xian Cui; Liangjun Hu; Yunchao Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

4.  Micronization of a soft material: air-jet and micro-ball milling.

Authors:  Imran Y Saleem; Hugh D C Smyth
Journal:  AAPS PharmSciTech       Date:  2010-11-24       Impact factor: 3.246

5.  A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.

Authors:  Juan W Valle; Anne Armstrong; Chris Newman; Valery Alakhov; Grzegorz Pietrzynski; Julie Brewer; Sue Campbell; Pippa Corrie; Eric K Rowinsky; Malcolm Ranson
Journal:  Invest New Drugs       Date:  2010-02-24       Impact factor: 3.850

Review 6.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

7.  Effect of pluronic p85 on amino acid transport in bovine brain microvessel endothelial cells.

Authors:  Xiaobin Zhang; Daria Y Alakhova; Elena V Batrakova; Shu Li; Zhihui Yang; Yili Li; Alexander V Kabanov
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-02       Impact factor: 4.147

Review 8.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

Review 9.  Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.

Authors:  Mayur M Patel; Bhoomika M Patel
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 10.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.